Boston University School of Medicine

Study of GLEAMER Artificial Intelligence Software Wins RSNA Alexander R. Margulis Award for Scientific Excellence

Retrieved on: 
Monday, November 28, 2022

PARIS, Nov. 28, 2022 /PRNewswire/ -- A U.S. study of BoneView by GLEAMER AI software led by Ali Guermazi, MD, PhD, Chief of Radiology at VA Boston Healthcare System and Professor of Radiology and Medicine at Boston University School of Medicine, has been honored with the 2022 Alexander R. Margulis Award for Scientific Excellence. The award recognizes the best original scientific article for a given year of the hundreds published in Radiology, the premier publication of The Radiological Society of North America (RSNA), an international society of radiologists, medical physicists and other medical imaging professionals representing 31 radiologic subspecialties from 145 countries around the world.

Key Points: 
  • The Margulis Award Nominating Committee and the Margulis Award Selection Committee review published manuscripts based on their novelty, quality, importance and potential scientific and clinical impacts.
  • The committees selected Dr. Guermazi's work, Improving Radiographic Fracture Recognition Performance and Efficiency Using Artificial Intelligence , published in Vol.
  • Our study was focused on fracture diagnosis, and a similar concept can be applied to other diseases and disorders."
  • GLEAMER's first globally available AI software, BoneView, is cleared by the U.S. Federal Food and Drug Administration and has CE mark class IIa certification in Europe.

Orthopaedic Spine Surgeon Dr. Sonny Gill Joins The Steadman Clinic Surgical Team

Retrieved on: 
Monday, November 21, 2022

VAIL, Colo., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Orthopaedic spine surgeon Sonny Gill, M.D., joins The Steadman Clinic surgical team on November 28, 2022.

Key Points: 
  • VAIL, Colo., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Orthopaedic spine surgeon Sonny Gill, M.D., joins The Steadman Clinic surgical team on November 28, 2022.
  • His appointment at The Steadman Clinic marks a return to the Vail Valley for Dr. Gill, who served as a fellow at The Steadman Clinic and Steadman Philippon Research Insitute (SPRI) from 200405 and also worked with the Clinic from 20082010.
  • We are so privileged to have Dr. Gill join our staff, said Dr. Philippon, managing partner of The Steadman Clinic and chair of Steadman Philippon Research Institute (SPRI).
  • He is one of the elite spine surgeons in our country and will make an immediate impact on our surgical team here at The Steadman Clinic.

JPMA Cares to Honor Dr. Sadiqa Kendi with the 2022 Impact Award

Retrieved on: 
Tuesday, November 1, 2022

MOUNT LAUREL, N.J., Nov. 1, 2022 /PRNewswire-PRWeb/ -- JPMA Cares is pleased to announce Dr. Sadiqa Kendi as the organization's 2022 Impact Award winner. Dr. Kendi serves as the Division Chief of the Pediatric Emergency Medicine Division and Associate Professor of Pediatrics at Boston Medical Center and Boston University School of Medicine. She is an expert in pediatric injury prevention, with a focus on health equity.

Key Points: 
  • JPMA Cares is pleased to announce Dr. Sadiqa Kendi as the organization's 2022 Impact Award winner.
  • MOUNT LAUREL, N.J., Nov. 1, 2022 /PRNewswire-PRWeb/ -- JPMA Cares is pleased to announce Dr. Sadiqa Kendi as the organization's 2022 Impact Award winner.
  • "We are thrilled to recognize Dr. Sadiqa Kendi for the tremendous work she's doing to make a positive impact on the long-term success of babies and young children," said Executive Director of JPMA and JPMA Cares Lisa Trofe.
  • "I'm honored to be recognized with the JPMA Cares Impact Award," said Dr. Kendi.

Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments

Retrieved on: 
Tuesday, October 11, 2022

WOBURN, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that it is building on its clinical development science and operations capabilities through recent key appointments. These appointments include: Gabriel Belfort, MD, PhD, Vice President, Clinical Development Sciences and Operations, Kelly Bourdon, Head of Clinical Operations, Philinia Lehr RN, MSN, Head of Clinical Trial Recruitment and Margaret Nelson-Lowe, PhD, Associate Director, Clinical Operations.

Key Points: 
  • - Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 -
    WOBURN, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that it is building on its clinical development science and operations capabilities through recent key appointments.
  • These appointments include: Gabriel Belfort, MD, PhD, Vice President, Clinical Development Sciences and Operations, Kelly Bourdon, Head of Clinical Operations, Philinia Lehr RN, MSN, Head of Clinical Trial Recruitment and Margaret Nelson-Lowe, PhD, Associate Director, Clinical Operations.
  • We are excited to be moving to this next stage of the companys growth with the addition of these key clinical development team members as we advance our Phase 2b clinical trial for AB-2004 to treat irritability associated with autism, said Stew Campbell, CEO of Axial Therapeutics.
  • Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions.

Q32 Bio, a Clinical Stage Biotechnology Company Focused on Therapeutics that Restore Immune Homeostasis, Announces CEO Transition

Retrieved on: 
Tuesday, September 20, 2022

WALTHAM, Mass., Sept. 20, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Jodie Morrison as Board Member and Acting Chief Executive Officer, succeeding Michael Broxson.

Key Points: 
  • WALTHAM,Mass., Sept. 20, 2022 /PRNewswire/ -- Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Jodie Morrison as Board Member and Acting Chief Executive Officer, succeeding Michael Broxson.
  • During his tenure as CEO, Mr. Broxson helped Q32 Bio progress from an early-stage clinical company to one with a robust pipeline and two rapidly progressing clinical programs.
  • Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to re-balance immunity in severe autoimmune and inflammatory diseases.
  • Q32 Bio is currently conducting a first-in-human, Phase 1, ascending dose (SAD/MAD) clinical study of ADX-097 for the treatment of complement disorders.

Nathan S. Bryan, Ph.D Book, "The Secret Of Nitric Oxide - Bringing Nitric Oxide To Life" Sold to J. Boylston & Company Publishers by Agent Alan Morell, Creative Management Partners (CMP)

Retrieved on: 
Thursday, September 15, 2022

BEVERLY HILLS, CA, Sept. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Announced today:  Nathan S. Bryan, Ph.D book, The Secret Of Nitric Oxide—Bringing Nitric Oxide To Life, sold to J. Boylston & Company Publishers by Agent Alan Morell, Creative Management Partners (CMP).

Key Points: 
  • Book adapted for TV Documentary; 48 City Satellite Media Tour; Podcast Series; Instagram Campaign and Book Tour; Worldwide Licensing and Media Positioning coordinated by CMP.
  • BEVERLY HILLS, CA, Sept. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Announced today:Nathan S. Bryan, Ph.D book, The Secret Of Nitric OxideBringing Nitric Oxide To Life, sold to J. Boylston & Company Publishers by Agent Alan Morell, Creative Management Partners (CMP).
  • Said Publisher John T. Colby Jr: On behalf of J. Boylston & Company Publishers, we are excited to work with Dr. Bryan and his Agent Alan Morell at CMP to make The Secret Of Nitric OxideBringing Nitric Oxide To Life a best seller.
  • Bryan is an international leader in molecular medicine and nitric oxide biochemistry.

Study of Constant Therapy Shows Promise of Sustained Cognitive Function in Alzheimer’s Disease Patients

Retrieved on: 
Monday, September 12, 2022

LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Constant Therapy Health , a brain health digital therapeutics company, announced today the publication of a feasibility study of its Constant Therapy digital cognitive therapy platform in the Journal of Medical Internet Research (JMIR) titled, Home-based electronic cognitive therapy in patients with Alzheimer Disease: Feasibility Randomized Controlled Trial .

Key Points: 
  • LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Constant Therapy Health , a brain health digital therapeutics company, announced today the publication of a feasibility study of its Constant Therapy digital cognitive therapy platform in the Journal of Medical Internet Research (JMIR) titled, Home-based electronic cognitive therapy in patients with Alzheimer Disease: Feasibility Randomized Controlled Trial .
  • Patients engaged more with Constant Therapy compared to paper and pencil training over the 24-week study period and improved their performance over time.
  • The goal of the study was to determine the feasibility of a long-term home-based cognitive training intervention for patients with mild dementia from Alzheimers disease.
  • This latest study shows that Constant Therapy is a promising digital home-based option for people with Alzheimers disease with mild dementia or MCI, to help patients maintain cognitive and communication skills longer.

Rimidi and Boston Medical Center Release Metrics from Ongoing Remote Monitoring Program for Postpartum Hypertension

Retrieved on: 
Tuesday, August 30, 2022

ATLANTA and BOSTON, Aug. 30, 2022  /PRNewswire-PRWeb/ -- Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, and Boston Medical Center, a private, not-for-profit academic medical center in New England, today released metrics from an ongoing remote patient monitoring program for new moms at high-risk of postpartum hypertension.

Key Points: 
  • ATLANTA and BOSTON, Aug. 30, 2022 /PRNewswire-PRWeb/ -- Rimidi , a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, and Boston Medical Center , a private, not-for-profit academic medical center in New England, today released metrics from an ongoing remote patient monitoring program for new moms at high-risk of postpartum hypertension.
  • To address this challenge, Boston Medical Center leveraged the Rimidi platform to bring remotely-generated patient data from cellular-connected blood pressure cuffs into their clinical workflow.
  • Boston Medical Center (BMC) is a private, not-for-profit, 514-bed, academic medical center that is the primary teaching affiliate of Boston University School of Medicine.
  • Boston Medical Center and Boston University School of Medicine are partners in Boston HealthNet 12 community health centers focused on providing exceptional health care to residents of Boston.

Verséa Holdings, Inc. welcomes Rob Sambursky, MD, as President to lead the company’s expansion into the ophthalmic market

Retrieved on: 
Tuesday, August 16, 2022

Dr. Sambursky will support corporate strategy and operations as well as lead the companys expansion into the ophthalmic market.

Key Points: 
  • Dr. Sambursky will support corporate strategy and operations as well as lead the companys expansion into the ophthalmic market.
  • Versa recently launched a new business division, Versa Ophthalmics, with a goal of providing innovative solutions for the diagnosis, treatment, and management of ocular surface diseases.
  • We are very pleased to welcome Rob to the Versa team, said Sean Fetcho, the CEO and co-founder of Versa.
  • He will be extremely valuable as we expand into the ophthalmic market and grow Versa into an eye care industry leader.

AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases

Retrieved on: 
Thursday, August 11, 2022

Management will also discuss the advantages offered by the innovative biomarker-based clinical trial designs being utilized in its Alzheimers and Parkinsons disease programs.

Key Points: 
  • Management will also discuss the advantages offered by the innovative biomarker-based clinical trial designs being utilized in its Alzheimers and Parkinsons disease programs.
  • Her research focuses on understanding and using the immune system therapeutically to prevent and treat Alzheimer's disease.
  • AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and NeuroOrphan indications driven by misfolded proteins.
  • Morphomer is a registered trademark of AC Immune SA in CN, CH, GB, JP, NO and RU.